true 0001785173 0001785173 2024-07-30 2024-07-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

(Amendment No. 1)

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 30, 2024

 

 

89bio, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39122   36-4946844

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

142 Sansome Street, Second Floor

San Francisco, CA 94104

(Address of principal executive offices, including zip code)

(415) 432-9270

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   ETNB   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

This Amendment No. 1 to Current Report on Form 8-K (this “Form 8-K/A”) amends the Current Report on Form 8-K filed by 89bio, Inc. (the “Company”) on August 5, 2024 (the “Initial Form 8-K”). The Initial Form 8-K reported the appointment of Charles McWherter, Ph.D. as a member of the board of directors of the Company (the “Board”). Pursuant to Instruction 2 to Item 5.02 of Form 8-K, this Form 8-K/A is being filed to disclose committee assignments for Dr. McWherter, which had not been determined at the time of filing of the Initial Form 8-K. No other changes have been made to the Initial Form 8-K.

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Committee Appointment

On October 29, 2024, the Board appointed Dr. McWherter to serve on the Board’s Nominating and Corporate Governance Committee and Science and Technology Committee, effective October 29, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    89bio, Inc.
Date: October 30, 2024     By:  

/s/ Rohan Palekar

      Rohan Palekar
      Chief Executive Officer
v3.24.3
Document and Entity Information
Jul. 30, 2024
Cover [Abstract]  
Amendment Flag true
Entity Central Index Key 0001785173
Document Type 8-K/A
Document Period End Date Jul. 30, 2024
Entity Registrant Name 89bio, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39122
Entity Tax Identification Number 36-4946844
Entity Address, Address Line One 142 Sansome Street
Entity Address, Address Line Two Second Floor
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code (415)
Local Phone Number 432-9270
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol ETNB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Description This Amendment No. 1 to Current Report on Form 8-K (this “Form 8-K/A”) amends the Current Report on Form 8-K filed by 89bio, Inc. (the “Company”) on August 5, 2024 (the “Initial Form 8-K”). The Initial Form 8-K reported the appointment of Charles McWherter, Ph.D. as a member of the board of directors of the Company (the “Board”). Pursuant to Instruction 2 to Item 5.02 of Form 8-K, this Form 8-K/A is being filed to disclose committee assignments for Dr. McWherter, which had not been determined at the time of filing of the Initial Form 8-K. No other changes have been made to the Initial Form 8-K.
89bio (NASDAQ:ETNB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas 89bio.
89bio (NASDAQ:ETNB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas 89bio.